Eupraxia Pharmaceuticals (EPRX) Investment Income (2023 - 2024)
Eupraxia Pharmaceuticals' (EPRX) quarterly Investment Income came in at -$32392.0 in Q1 2024, down 486.71% year-on-year from $8376.4 in Q2 2023, and down 486.71% on a QoQ basis from -$5521.0 in Q1 2023.
Eupraxia Pharmaceuticals (EPRX) Investment Income (2023 - 2024) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 2 years of Investment Income data on file, last reported at -$32392.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inv. Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Eupraxia Pharmaceuticals | 346.51 Mn | 346.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -32,392.00 |
| Mar 31, 2023 | -5,521.00 |